{
    "nctId": "NCT01047358",
    "briefTitle": "Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer",
    "officialTitle": "Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 206,
    "primaryOutcomeMeasure": "Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* - Postmenopausal women with breast cancer eligible for hormonal therapy.\n\nExclusion Criteria:\n\n* Pregnant breast-feeding premenopausal.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}